GSK plc (NYSE: GSK) is 0.63% higher on its value in year-to-date trading and has touched a low of $28.47 and a high of $47.82 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GSK stock was last observed hovering at around $35.38 in the last trading session, with the day’s loss setting it -0.02% off its average median price target of $38.43 for the next 12 months. It is also 42.86% off the consensus price target high of $61.88 offered by 21 analysts, but current levels are -17.12% lower than the price target low of $30.19 for the same period.
Currently trading at $35.36, the stock is 0.76% and 1.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.96 million and changing -0.06% at the moment leaves the stock -6.76% off its SMA200. GSK registered -22.61% loss for a year compared to 6-month loss of -16.39%.
The stock witnessed a 1.06% gain in the last 1 month and extending the period to 3 months gives it a 13.84%, and is -0.06% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.06% over the week and 1.30% over the month.
GSK plc (GSK) has around 90096 employees, a market worth around $71.67B and $38.99B in sales. Current P/E ratio is 14.39 and Fwd P/E is 9.77. Profit margin for the company is 43.50%. Distance from 52-week low is 24.22% and -26.05% from its 52-week high. The company has generated returns on investments over the last 12 months (14.80%).
GSK plc (GSK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for GSK plc (GSK) is a “Hold”. 21 analysts offering their recommendations for the stock have an average rating of 2.80, where 12 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
GSK plc is expected to release its quarterly report on 04/26/2023.The EPS is expected to shrink by -24.10% this year.
GSK plc (GSK) Top Institutional Holders
The shares outstanding are 2.04B, and float is at 2.00B with Short Float at 0.42%.
GSK plc (GSK) Insider Activity
A total of 0 insider transactions have happened at GSK plc (GSK) in the last six months, with sales accounting for 0 and purchases happening 0 times.
GSK plc (GSK): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 12.36% up over the past 12 months and Sanofi (SNY) that is -6.14% lower over the same period. Pfizer Inc. (PFE) is -16.78% down on the 1-year trading charts.